Eosinophilic gastritis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:30:49 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Eosinophilic gastritis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effectiveness of Dupilumab for Adults and Adolescents with Eosinophilic Gastritis and Eosinophilic Duodenitis https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-dupilumab-for-adults-and-adolescents-with-eosinophilic-gastritis-and-eosinophilic-duodenitis/ Wed, 29 Apr 2026 14:26:41 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-dupilumab-for-adults-and-adolescents-with-eosinophilic-gastritis-and-eosinophilic-duodenitis/ This clinical trial is focused on studying the effects of a medication called dupilumab on a condition known as eosinophilic gastritis, which may occur with or without eosinophilic duodenitis. Eosinophilic gastritis is a condition where a type of white blood cell, called an eosinophil, builds up in the stomach lining, causing inflammation and discomfort. Eosinophilic duodenitis is similar but occurs in the first part of the small intestine. The study will compare the effects of dupilumab, which is given as a solution for injection, to a placebo, which looks like the medication but does not contain the active ingredient.

The purpose of the study is to determine if dupilumab is safe and effective in treating adults and adolescents with eosinophilic gastritis, with or without eosinophilic duodenitis. Participants in the study will receive either dupilumab or a placebo over a period of up to 52 weeks. The study is divided into three parts, with each part focusing on different aspects of treatment and safety. Throughout the study, participants will undergo various assessments to monitor the effects of the treatment on their condition.

Participants will receive regular injections and will be monitored for changes in their symptoms and any side effects. The study aims to provide valuable information on how well dupilumab works in reducing the symptoms and inflammation associated with eosinophilic gastritis and eosinophilic duodenitis. This research could lead to better treatment options for individuals affected by these conditions.

]]>